Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results

Masakazu Ichinose,1 Hiroyuki Nakamura,2 Noriharu Shijubo,3 Takefumi Saito,4 Hiroyuki Taniguchi,5 Toru Tsuda,6 Kosho Yoshikawa,7 Lars-Goran Carlsson8

1Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; 2Sakaide City Hospital, Kagawa, Japan; 3JR Sapporo Hospital, Hokkaido, Japan; 4National Hospital Organization Ibarakihigashi National Hospital, Ibaraki, Japan; 5Tosei General Hospital, Aichi, Japan; 6Kirigaoka Tsuda Hospital, Fukuoka, Japan; 7Daido Hospital, Aichi, Japan; 8AstraZeneca R&D, Molndal, Sweden.

Background: This study evaluated the tolerability and efficacy of budesonide/formoterol (BUD/FORM) vs standard COPD treatment (SCT) in Japanese patients with moderate to severe COPD.

Methods: In this randomised, open-label, parallel-group, phase III study (NCT01070784), patients ≥40 years of age with moderate to severe COPD for ≥2 years received either BUD/FORM 160/4.5µg 2 inhalations bid via Turbuhaler® or SCT (as judged by the investigator) for 52 weeks. Reliever medication: salbutamol via pMDI. Primary outcome: nature, incidence and severity of adverse events (AEs). Secondary outcome variables included: COPD symptoms, lung function and exacerbations.

Results: 260 patients were randomised. BUD/FORM was well tolerated; 404 AEs were reported by 123 patients (94.6%) receiving BUD/FORM vs. 367 AEs by 112 patients (86.2%) on SCT. Majority of AEs were of mild or moderate intensity and the AE profile was similar in the two groups. Most commonly reported AEs (BUD/FORM vs SCT) were nasopharyngitis (42.3% vs 39.2%), COPD (10.8% vs 19.2%) and bronchitis (11.5% vs 11.5%). Frequency of pneumonia-related AEs was similar in both groups (13.1% vs 12.3%) while dysphonia was more frequent with BUD/FORM (5.4% vs 0.8%). Serious AEs were more frequent with SCT (26.2%) vs. BUD/FORM (19.2%). No deaths were reported. Efficacy of BUD/FORM was maintained over 52 weeks.

Conclusions: BUD/FORM 160/4.5µg 2 inhalations bid was well tolerated and efficacy was maintained during 52-week treatment in Japanese patients with moderate to severe COPD.

Funding: AstraZeneca

Character count: 1808 characters (Max: 1789 characters including title and body text)